"Site-restricted conjugation of native mAbs offers the best of two worlds"Read more
The Linxis management has developed its in-company IP strategy to ensure the protection of her proprietary Lx®-ADC technology with several patent applications.
Other patent applications for the Lx®-ADC technology are pending. In addition to these applications, Linxis will continue to investigate her Freedom to Operate and file patents protecting new developments and ADC products.
Method for removing weakly bound functional moieties from cell targeting conjugates, September 2016November 2017
Method for preparing cell targeting conjugates, and the complexes obtained, July 2013November 2017